testolactone
Trade name: teslac
Small moleculeapproved
Approved
Jun 3, 1969
Testolactone (Teslac brand name) is an anti-cancer agent, which was used as adjunctive therapy in the palliative treatment of advanced or disseminated breast cancer. The mechanism of testolactone action is reported to be related to the inhibition of aromatase enzymatic activity. Testolactone is no longer available in the USA. — NCATS
Clinical trial activity
3 trials · 1 clinical orgs · 2 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 1982 (NCT00001181)
Timeline
1960s
- Jun 3, 1969
Earliest FDA Approval
- Jun 3, 1969
Bristol-Myers Squibb — NDA Secondary Org
1970s
- May 27, 1970
Bristol-Myers — First NDA Organization
- May 27, 1970
Bristol-Myers — NDA Organization
1980s
- Jan 1, 1982
Earliest Phase 2 Sponsor(trial)
1990s
- Jan 1, 1996
Earliest Phase 1 Sponsor(trial)
Indications
Approved for
Mechanism of action
- Cytochrome P450 19A1INHIBITOR
CYP19A1 inhibitor
Approval history
- approvedJun 3, 1969
Chemistry & pharmacology
Loading structure…
SMILES
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CCC(=O)O2- Mol. weight
- 300.3921 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral, Parenteral
- Availability
- Discontinued
Oral
Yes
Parenteral
Yes
Topical
No
Sources
- WikipediaTestolactone ↗
- NCATS6J9BLA949Q ↗
- ChEMBLCHEMBL1571 ↗
Also known as
- 1,2-didehydrotestololactone
- 1,2-didehydrotestololactone
- 13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid δ-lactone
- 13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid δ-lactone
- 1-dehydrotestololactone
- 1-dehydrotestololactone
- (4as,4br,10ar,10bs,12as)-10a,12a-dimethyl-3,4,4a,5,6,10a,10b,11,12,12a-decahydro-2h-naphtho[2,1-f]chromene-2,8(4bh)-dione
- (4as,4br,10ar,10bs,12as)-10a,12a-dimethyl-3,4,4a,5,6,10a,10b,11,12,12a-decahydro-2h-naphtho[2,1-f]chromene-2,8(4bh)-dione
- delta(1)-testololactone
- delta(1)-testololactone
- d-homo-17a-oxaandrosta-1,4-diene-3,17-dione
- d-homo-17a-oxaandrosta-1,4-diene-3,17-dione
- fludestrin
- fludestrin
- fludestrin
- sq-9538
- sq-9538
- teolit
- teslac
- teslac
- teslac
- teslac
- teslac
- teslac
- teslac
- testolacton
- testolactona
- testolactona
- testolactone
- testolactone
- testolactone
- testolactone
- testolactone
- testolactone
- testolactone
- testolactone
- testolactone
- testolactone
- testolactonum
- testolactonum
- testolattone
- testolattone
- δ1-testololactone
- δ1-testololactone
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00001521 | Phase 1 | Feb 2, 1996 | National Institutes of Health (NIH) |
| NCT00001202 | Phase 2 | Jan 1, 1985 | National Institutes of Health (NIH) |
| NCT00001181 | Phase 2 | Oct 1, 1982 | National Institutes of Health (NIH) |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institutes of Health (NIH) | Government | 3 | 3 | 2 | 1982 |
1 organizations
Page 1 / 1
Marketing (2)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Bristol-Myers | For profit | NDA | May 27, 1970 |
| Bristol-Myers Squibb | For profit | NDA2 | Jun 3, 1969 |